Skip to main content
TNGX logo

Tango Therapeutics, Inc. (TNGX) Stock: Price, Forecast & Analyst Target

Tango Therapeutics, Inc. (TNGX) — MoonshotScore 62/100 (Fair band), calculated Nov 18, 2026. Price $21.89 (-1.00%), as of the Nov 18, 2026 trading session; market cap $3.71B.

Educational signal · not a buy or sell recommendation · How to read this

$21.89 −$0.22 (-1.00%) Market Cap $3.71B

Tango Therapeutics, Inc. · TNGX · NASDAQ

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing precision oncology therapies using a synthetic lethal approach. Its pipeline includes small molecule inhibitors targeting cancers with specific genetic vulnerabilities, supported by a strategic collaboration with Gilead Sciences.

Price as of Nov 18, 2026

Key Statistics

62 of 100

MoonshotScore v2 · Tango Therapeutics (TNGX)

Fair
Business Quality Average (46)
Financial Safety Fortress (94)
Valuation Full (55)
Growth Durability Shrinking (8)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.

  • quarterly revenue $54M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 2 of the last 8 reports
  • Altman Z 41.83 · Piotroski F 2

Holding back: soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TNGX (57 recorded, newest six shown)
RecordedScoreBand
68Strong
68Strong
77Strong
77Strong
62Fair
62Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$21.89
Change on the day-1.00%
Market capitalisation$3.71B—
Shares traded on the day2.75M

Price & events

Other perspectives

Council score for Tango Therapeutics (TNGX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Strong
Valuation Neutral
Growth Durability Negative
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Tango Therapeutics (TNGX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Tango Therapeutics, Inc. (TNGX) is listed on NASDAQ. It employs 137 people. In Q3 FY2025 it reported revenue of $54M and net income of $16M. The market values it at $3.71B.

2 · Latest results

What do the latest results show for Tango Therapeutics (TNGX)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $54M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$54M$16M$0.13 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Tango Therapeutics (TNGX)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 41.83 · Piotroski F 2. Trailing ratios: ROE -30.3% · ROA -20.1% · current ratio 39.45 · earnings yield -4.9% · free-cash-flow yield -3.7%.

Data-derived red flags

  • Negative return on equity (-30.3%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Tango Therapeutics (TNGX)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $6.06M · EPS -1.50 · 8 analysts. Current published price targets run low $35.00 · high $69.00 · consensus $50.50 · median $46.50 against a quoted price of $21.89 (as of Nov 18, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Nov 4, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Tango Therapeutics compare with its peers?

Short answer

Tango Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.65 Nov 18, 2026$2.99B95 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.37 Nov 18, 2026$4.53B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$44.89 Nov 18, 2026$3.30B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.76 Nov 18, 2026$4.83B67 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.74 Nov 18, 2026$6.49B67 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.62 Nov 18, 2026$3.42B66 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.86 Nov 18, 2026$5.27B66 5-pillar Nov 18, 2026
Tango Therapeutics (TNGX) — this page$21.89$3.71B62

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$35.00 – $69.00
Consensus target
$50.50
Median target
$46.50
Revenue estimate
$6.06M
EPS estimate
$-1.50

Consensus record · Captured .

Measured against a quoted price of $21.89 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
41
Identified insiders
7
Purchases
0
Sales
17
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TNGX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TNGX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Tango Therapeutics (TNGX)?

Read these with our analysis →

Tango Therapeutics Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the TNGX research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for TNGX?

TNGX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is TNGX a good stock to buy?

Stock Expert AI does not rate TNGX buy, sell or hold. Tango Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TNGX stock price today?

The last price recorded for Tango Therapeutics, Inc. (TNGX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TNGX price target?

The analyst consensus price target for Tango Therapeutics, Inc. (TNGX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

How does Tango Therapeutics, Inc.'s strategic collaboration with Gilead Sciences impact its operations?

The strategic collaboration with Gilead Sciences, Inc. is a cornerstone of Tango Therapeutics' operational and financial strategy. This partnership provides significant non-dilutive funding, which is crucial for a clinical-stage biotechnology company with substantial research and development costs.

What are the key factors to evaluate for TNGX?

Tango Therapeutics, Inc. (TNGX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic Collaboration: The ongoing strategic collaboration with Gilead Sciences, Inc. is a critical operational highlight, providing significant financial support and validation for Tango's drug discovery and development efforts in oncology. Not financial advice.

How frequently does TNGX data refresh on this page?

TNGX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TNGX's recent stock price performance?

Tango Therapeutics, Inc. (TNGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized synthetic lethality drug discovery platform with a focus on precision oncology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TNGX overvalued or undervalued right now?

Tango Therapeutics, Inc. (TNGX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.